17 October 2024
Futura Medical plc
("Futura", "the Group" or the "Company")
Clinical trial data presented at SMSNA
Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that three abstracts on MED3000 are being presented at the Sexual Medicine Society of North America (SMSNA) at their annual conference in Scottsdale, Arizona on 17th to 20th October. The SMSNA promotes, encourages, and supports the highest standards of practice, research, education, and ethics in the study of human sexual function and dysfunction.
The abstracts detail the results of clinical trials, showing the positive impact of MED3000 on Erectile Dysfunction (ED) but also self-esteem and relationships in men with ED and sexual encounter profiles for men and their partners.
The importance of the presentation of these abstracts is to educate and improve awareness amongst key opinion leaders and other healthcare practitioners about the benefits of MED3000 (now available through the USA under the brand name Eroxon®) as a clinical proven treatment for ED.
Details of the of the abstracts, methods and results can be found at: https://www.smsna.org/annual2024/program
| Abstract 1 | Topical Administration of MED3000 Gel Significantly Improves Self-esteem and Relationships in Men with Erectile Dysfunction: Results from Two Clinical Trials |
| Abstract 2 | Topical Administration of MED3000 Gel Significantly Improves Erectile Function in Men with Mild, Moderate, or Severe Erectile Dysfunction: Results from Two Multicenter Clinical Trials |
| Abstract 3 | Topical Administration of MED3000 Gel Significantly Improves All Aspects of the Sexual Encounter Profile for Both Men and Their Partners |
The abstracts are presented to the audience and then all abstracts presented at the meeting will be published in a supplement of the Journal of Sexual Medicine.
Contacts:
| Futura Medical plc
| James Barder Chief Executive Officer Angela Hildreth Finance Director and COO
| investor.relations@futuramedical.com +44 (0)1483 685 670
|
| Panmure Liberum Nominated Adviser and Broker
| Emma Earl, Will Goode, Rupert Dearden (Corporate Broking) | +44 (0)20 3100 2000
|
|
| | |
| Stifel Nicolaus Europe Limited Joint Broker
| Alan Selby Ben Maddison
| +44 (0)207 710 7600
|
|
| | |
| Alma Strategic Communications | Rebecca Sanders-Hewett Sam Modlin Will Ellis Hancock | +44 (0)20 3405 0205 futura@almastrategic.com |
| | | |
Notes to Editors:
Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.
Eroxon, Futura's clinically proven lead product, has been developed for the treatment of Erectile Dysfunction ("ED"). The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market.
ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40.
Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe. Eroxon has been nominated for a number of healthcare industry awards and has won two to-date.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
